Hepatitis B Virus Reactivation Potentiated by Biologics.
Hepatitis B virus
Nucleos(t)ide analogue
Prophylaxis
Reactivation
Journal
Infectious disease clinics of North America
ISSN: 1557-9824
Titre abrégé: Infect Dis Clin North Am
Pays: United States
ID NLM: 8804508
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
pubmed:
27
4
2020
medline:
16
3
2021
entrez:
27
4
2020
Statut:
ppublish
Résumé
Hepatitis B virus (HBV) reactivation can be a serious complication for patients with chronic or resolved HBV infection when treated with biologics. For HBsAg-positive patients receiving biologics, the risk of HBV reactivation is moderate to high. HBsAg-negative/anti-HBc positive patients are at lower risk of HBV reactivation than HBsAg-positive patients. However, patients taking anti-CD20 agents, such as rituximab, have high risk of HBV reactivation (>10%), so antiviral prophylactic therapies are required. This review provides the different classes of biologics associated with HBV reactivation, stratifies the various reactivation risk levels by HBV status and biologic agent, and discusses management strategies.
Identifiants
pubmed: 32334985
pii: S0891-5520(20)30011-8
doi: 10.1016/j.idc.2020.02.009
pii:
doi:
Substances chimiques
Biological Factors
0
Nucleosides
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
341-358Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure M.H. Nguyen: Grant/research support: Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceutical; Advisory board/consultant: Dynavax Laboratories, Gilead Sciences, Intercept Pharmaceutical; Anylam Pharmaceutical; Roche Laboratories; and Novartis Pharmaceuticals. The other authors have nothing to disclose.